Mesh.i
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Mesh.i » - entrée « Clinical Trials, Phase III as Topic »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Clinical Trials, Phase II as Topic < Clinical Trials, Phase III as Topic < Clinical Trials, Phase IV as Topic  Facettes :

List of bibliographic references indexed by Clinical Trials, Phase III as Topic

Number of relevant bibliographic references: 15.
Ident.Authors (with country if any)Title
001442 (2018) Tomohiro Koga [Japon] ; Shuntaro Sato [Japon] ; Junya Miyamoto [Japon] ; Naoko Hagimori [Japon] ; Yurika Kawazoe [Japon] ; Kumiko Arinaga [Japon] ; Chizu Fukushima [Japon] ; Hiroshi Yamamoto [Japon] ; Atsushi Kawakami [Japon]Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
001757 (2017) Gerd R. Burmester [Allemagne] ; Ernest Choy [Royaume-Uni] ; Alan Kivitz [États-Unis] ; Atsushi Ogata [Japon] ; Min Bao [États-Unis] ; Akira Nomura [Japon] ; Stuart Lacey [Royaume-Uni] ; Jinglan Pei [États-Unis] ; William Reiss [États-Unis] ; Attila Pethoe-Schramm [Suisse] ; Navita L. Mallalieu [États-Unis] ; Thomas Wallace [États-Unis] ; Margaret Michalska [États-Unis] ; Herbert Birnboeck [Suisse] ; Kay Stubenrauch [Allemagne] ; Mark C. Genovese [États-Unis]Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
001834 (2017) Robert J. Moots [Royaume-Uni] ; Anthony Sebba [États-Unis] ; William Rigby [États-Unis] ; Andrew Ostor ; Benjamin Porter-Brown [Royaume-Uni] ; Francis Donaldson [Royaume-Uni] ; Sophie Dimonaco [Royaume-Uni] ; Andrea Rubbert-Roth [Allemagne] ; Ronald Van Vollenhoven [Suède] ; Mark C. Genovese [États-Unis]Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.
001A49 (2016) Simon Cooper [États-Unis]Sarilumab for the treatment of rheumatoid arthritis.
001E63 (2015) Soken-Nakazawa J. Song [Japon] ; Kazuyuki YoshizakiTocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
002270 (2014) Norihiro Nishimoto[Programs for continuing medical education: a session; 8. Pharmacotherapy of rheumatoid arthritis--interleukin-6 blocker made in Japan].
002750 (2013) Gustavo Carbone [États-Unis] ; Augusta Wilson ; Sean A. Diehl ; Janice Bunn ; Sheldon M. Cooper ; Mercedes RinconInterleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis.
002768 (2013) J. Wang [Royaume-Uni] ; A T Bansal ; M. Martin ; S. Germer ; R. Benayed ; L. Essioux ; J S Lee ; A. Begovich ; A. Hemmings ; A. Kenwright ; K E Taylor ; R. Upmanyu ; P. Cutler ; O. Harari ; J. Marchini ; L A Criswell ; Adam PlattGenome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.
003480 (2012) Karel Pavelka [République tchèque] ; Arthur F. Kavanaugh ; Andrea Rubbert-Roth ; Gianfranco FerraccioliOptimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.
003882 (2011) Akira Sagawa [Japon]The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
003938 (2011) Janet S. Lee [États-Unis] ; Jianmei Wang ; Mitchell Martin ; Soren Germer ; Andrew Kenwright ; Ryma Benayed ; Olivia Spleiss ; Adam Platt ; Robert Pilson ; Andrew Hemmings ; Michael E. Weinblatt ; Neil Kaplowitz ; Joel KrasnowGenetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab.
003E87 (2009) Robert J. Moots [Royaume-Uni] ; Andrew Jk Ostör ; John D. IsaacsWill treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?
004073 (2008) Sheila A. Doggrell [Australie]Is tocilizumab an option for the treatment of arthritis?
004078 (2008) Ernest Choy [Royaume-Uni]Inhibiting interleukin-6 in rheumatoid arthritis.
004406 (????) Jeremy A. Schafer [États-Unis] ; Nicole K. Kjesbo ; Patrick P. GleasonFormulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Clinical Trials, Phase III as Topic" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Clinical Trials, Phase III as Topic" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Clinical Trials, Phase III as Topic
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021